Acadian Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13M Sell
102,866
-164,780
-62% -$21.7M 0.02% 516
2026
Q1
$37.3M Sell
267,646
-609,639
-69% -$85.4M 0.05% 277
2025
Q4
$108M Buy
877,285
+107,802
+14% +$13.1M 0.18% 115
2025
Q3
$85.4M Buy
769,483
+1,629
+0.2% +$185K 0.15% 134
2025
Q2
$85.1M Buy
767,854
+372,374
+94% +$39.6M 0.18% 116
2025
Q1
$44.3M Buy
395,480
+189,569
+92% +$19.6M 0.13% 148
2024
Q4
$19M Sell
205,911
-15,651
-7% -$1.41M 0.06% 243
2024
Q3
$18.6M Sell
221,562
-67,101
-23% -$5.12M 0.06% 237
2024
Q2
$19.8M Sell
288,663
-52,674
-15% -$3.52M 0.06% 240
2024
Q1
$25M Sell
341,337
-325,625
-49% -$25M 0.09% 184
2023
Q4
$54M Sell
666,962
-174,817
-21% -$13.6M 0.21% 120
2023
Q3
$63.1M Sell
841,779
-906,707
-52% -$69.7M 0.26% 105
2023
Q2
$135M Sell
1,748,486
-59,923
-3% -$4.78M 0.55% 42
2023
Q1
$150M Sell
1,808,409
-129,509
-7% -$10.7M 0.66% 27
2022
Q4
$166M Sell
1,937,918
-315,848
-14% -$25M 0.82% 16
2022
Q3
$139M Buy
2,253,766
+152,669
+7% +$9.63M 0.76% 24
2022
Q2
$130M Sell
2,101,097
-4,045
-0.2% -$250K 0.66% 35
2022
Q1
$125M Buy
2,105,142
+1,531,864
+267% +$97.9M 0.52% 52
2021
Q4
$41.6M Sell
573,278
-789,280
-58% -$54.4M 0.16% 141
2021
Q3
$95.2M Sell
1,362,558
-1,229,391
-47% -$86.4M 0.36% 86
2021
Q2
$178M Buy
2,591,949
+122,146
+5% +$8.16M 0.67% 32
2021
Q1
$160M Buy
2,469,803
+158,183
+7% +$10.2M 0.62% 41
2020
Q4
$135M Buy
2,311,620
+59,190
+3% +$3.57M 0.52% 51
2020
Q3
$142M Buy
2,252,430
+774,961
+52% +$53.7M 0.6% 40
2020
Q2
$114M Buy
1,477,469
+649,946
+79% +$49.8M 0.49% 45
2020
Q1
$61.9M Buy
827,523
+698,896
+543% +$48.3M 0.35% 76
2019
Q4
$8.36M Buy
128,627
+93,685
+268% +$6.1M 0.04% 345
2019
Q3
$2.21M Buy
34,942
+6,361
+22% +$416K 0.01% 648
2019
Q2
$1.93M Sell
28,581
-66,194
-70% -$4.35M 0.01% 629
2019
Q1
$6.16M Buy
94,775
+60,691
+178% +$4.03M 0.03% 399
2018
Q4
$2.13M Buy
34,084
+5,679
+20% +$397K 0.01% 555
2018
Q3
$2.19M Buy
28,405
+19,450
+217% +$1.47M 0.01% 544
2018
Q2
$634K Buy
8,955
+9
+0.1% +$636 ﹤0.01% 838
2018
Q1
$675K Sell
8,946
-20,587
-70% -$1.64M ﹤0.01% 795
2017
Q4
$2.12M Buy
29,533
+3,415
+13% +$259K 0.01% 550
2017
Q3
$2.12M Buy
26,118
+12,584
+93% +$962K 0.01% 542
2017
Q2
$958K Sell
13,534
-9,234
-41% -$614K ﹤0.01% 712
2017
Q1
$1.55M Buy
22,768
+14,286
+168% +$1M 0.01% 684
2016
Q4
$606K Buy
8,482
+2,664
+46% +$198K ﹤0.01% 820
2016
Q3
$461K Sell
5,818
-6,099
-51% -$495K ﹤0.01% 830
2016
Q2
$993K Sell
11,917
-2,776
-19% -$246K 0.01% 640
2016
Q1
$1.35M Sell
14,693
-985
-6% -$88.8K 0.01% 602
2015
Q4
$1.59M Sell
15,678
-1,670
-10% -$174K 0.01% 615
2015
Q3
$1.7M Buy
17,348
+788
+5% +$87.5K 0.01% 582
2015
Q2
$1.94M Sell
16,560
-1,105
-6% -$121K 0.01% 572
2015
Q1
$1.73M Sell
17,665
-2,003
-10% -$203K 0.01% 572
2014
Q4
$1.85M Buy
19,668
+7,140
+57% +$738K 0.01% 538
2014
Q3
$1.33M Buy
12,528
+1,780
+17% +$174K 0.01% 539
2014
Q2
$891K Sell
10,748
-3,727
-26% -$290K ﹤0.01% 616
2014
Q1
$1.03M Buy
+14,475
New +$1.14M 0.01% 568

Other funds holding GILD

Acadian Asset Management's GILD Position: Q2 2026 in Review

Acadian Asset Management reduced its Gilead Sciences (GILD) stake by 62% in Q2 2026, selling an estimated $21.7M and leaving 102,866 shares worth $13M. The position accounts for 0.02% of the portfolio, ranked #516.

Acadian Asset Management first reported a position in GILD in Q1 2014 and has held it in 50 quarters since. The position peaked at $178M in Q2 2021. 1,917 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Acadian Asset Management held 102,866 shares of Gilead Sciences worth $13M as of Q2 2026.
  • Acadian Asset Management sold 164,780 Gilead Sciences shares in Q2 2026, an estimated $21.7M.
  • Gilead Sciences made up 0.02% of Acadian Asset Management's portfolio in Q2 2026, its #516 holding.
  • Acadian Asset Management first reported a position in Gilead Sciences in Q1 2014 and has held it in 50 quarters since.
  • Acadian Asset Management's Gilead Sciences position peaked at $178M in Q2 2021.
  • 1,917 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.